RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
溶瘤病毒癌症免疫治疗的新兴领域
英文原题：The emerging field of oncolytic virus-based cancer immunotherapy.
查看英文原题
The emerging field of oncolytic virus-based cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
溶瘤病毒（OVs）为对传统疗法耐药的癌症患者提供了新颖且有前景的治疗选择。天然或基因修饰的OVs是多方面的肿瘤杀手。它们直接裂解肿瘤细胞而不伤害正常细胞，并通过释放抗原和激活肿瘤微环境中的炎症反应间接增强抗肿瘤免疫。然而，一些局限性，如OVs对肿瘤的渗透有限、持续时间短以及宿主抗病毒免疫反应，正在阻碍溶瘤病毒疗法广泛转化为临床应用。如果这些挑战能够被克服，联合疗法，如OVs加免疫检查点阻断（ICB）、嵌合抗原受体（CAR）T细胞或CAR自然杀伤（NK）细胞，可能在临床上提供强大的治疗平台。
展开英文摘要原文
Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with cancers resistant to traditional therapies. Natural or genetically modified OVs are multifaceted tumor killers. They directly lyse tumor cells while sparing normal cells, and indirectly potentiate antitumor immunity by releasing antigens and activating inflammatory responses in the tumor microenvironment.
However, some limitations, such as limited penetration of OVs into tumors, short persistence, and the host antiviral immune response, are impeding the broad translation of oncolytic virotherapy into the clinic. If these challenges can be overcome, combination therapies, such as OVs plus immune checkpoint blockade (ICB), chimeric antigen receptor (CAR) T cells, or CAR natural killer (NK) cells, may provide powerful therapeutic platforms in the clinic.
论文信息
- 作者
- Ma R、Li Z、Chiocca EA、Caligiuri MA、Yu J
- 第一作者单位
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA; Laboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, PR China.United States
- 通讯作者单位
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA; Hematologic Malignancies Research Institute, City of Hope National Medical Center, Los Angeles, CA 91010, USA; Comprehensive Cancer Center, City of Hope, Los Angeles, CA 91010, USA; Department of Immuno-Oncology, Beckman Research Institute, Los Angeles, CA 91010, USA. Electronic address: jiayu@coh.org.United States
- 文献类型
- 综述 · 非美国政府资助研究 · 美国 NIH 资助研究
- 期刊
- Trends in cancer2023 Feb
- 原文标识
- PubMed 36402738 · DOI 10.1016/j.trecan.2022.10.003
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →